BRAINSTORM CELL THERAPEUTICS INC.

Q: Jun 30 2026

Q: Mar 31 2026

FY: Dec 31 2025

Q: Sep 30 2025

Q: Jun 30 2025

Q: Mar 31 2025

FY: Dec 31 2024

Q: Sep 30 2024

Q: Jun 30 2024

Q: Mar 31 2024

FY: Dec 31 2023

Q: Sep 30 2023

Q: Jun 30 2023

Q: Mar 31 2023

FY: Dec 31 2022

Q: Sep 30 2022

Q: Jun 30 2022

Q: Mar 31 2022

FY: Dec 31 2021

Q: Sep 30 2021

Results of Operations and Financial Condition

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Results of Operations and Financial Condition

Results of Operations and Financial Condition

Entry into a Material Definitive Agreement

Entry into a Material Definitive Agreement

Entry into a Material Definitive Agreement

Entry into a Material Definitive Agreement

Entry into a Material Definitive Agreement

Results of Operations and Financial Condition

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Other Events

Other Events

Results of Operations and Financial Condition

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

Entry into a Material Definitive Agreement

Results of Operations and Financial Condition

Other Events

Notice of Effectiveness

Registration (IPO) statement under Securities Act of 1933

Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans

Notification of removal from listing and/or registration on a national securities exchange

Withdrawal of a registration statement

Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans

Registration statement under Securities Act of 1933

Notice of Effectiveness

Registration statement under Securities Act of 1933 (amendment)

Registration statement under Securities Act of 1933

Notice of Effectiveness

Registration statement under Securities Act of 1933

Prospectus Supplement for Primary Offering

Prospectus Supplement for Primary Offering

Prospectus Supplement for Primary Offering

Prospectus Supplement for Primary Offering

Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans

Notice of Effectiveness

Registration statement under Securities Act of 1933

Prospectus Supplement for Primary Offering

Definitive Proxy Statement

Additional Information for Proxy Statement/ Votes

Preliminary Proxy Statement

Definitive Proxy Statement

No description available

Preliminary Proxy Statement

Additional Information for Proxy Statement/ Votes

Definitive Proxy Statement

Definitive Proxy Statement

Definitive Proxy Statement

Definitive Proxy Statement

Definitive Proxy Statement

Definitive Proxy Statement

Definitive Proxy Statement

Definitive Proxy Statement

Preliminary Proxy Statement

Definitive Proxy Statement

Preliminary Proxy Statement

Definitive Proxy Statement

Preliminary Proxy Statement

FRENKEL JACOB A

Pitts Peter Joe

Pitts Peter Joe

Yablonka Uri

Lebovits Chaim

ARBEL IRIT

FRENKEL JACOB A

Patlis Alla

Lindborg Stacy

HARTOUNIAN HARTOUN

Polverino Anthony J.

Bairu Menghisteab

Dagher Ibrahim B.

Naor Nir

ARMISTICE CAPITAL, LLC

ARMISTICE CAPITAL, LLC

Dagher Ibrahim B.

Dagher Ibrahim B.

ARBEL IRIT

Naor Nir

Correspondence with the SEC

Letter from the SEC

Annual Report Scanned (Paper)

Correspondence with the SEC

Correspondence with the SEC

Letter from the SEC

Correspondence with the SEC

Letter from the SEC

Annual Report Scanned (Paper)

Correspondence with the SEC

Letter from the SEC

Correspondence with the SEC

Letter from the SEC

Correspondence with the SEC

Letter from the SEC

Correspondence with the SEC

Letter from the SEC

Annual Report Scanned (Paper)

Correspondence with the SEC

Letter from the SEC